Sangart Initiates Study Of Hemospan In Chronic Critical Limb Ischemia

Armen Hareyan's picture

Sangart has started testing its lead product, Hemospan, in a Phase II clinical study involving chronic critical limb ischemia (CCLI) patients.

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.